Towards interferon-free treatment for all HCV genotypes

Affiliations

¹ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany. Electronic address: wedemeyer.heiner@mh-hannover.de.

Comment

Heiner Wedemeyer. Lancet. 2015.

. 2015 Jun 20;385(9986):2443-5.

doi: 10.1016/S0140-6736(15)60605-5. Epub 2015 Mar 31.

¹ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany. Electronic address: wedemeyer.heiner@mh-hannover.de.

No abstract available

Comment in

Interferon-free treatments against HCV are far from free.
Braillon A. Braillon A. Lancet. 2015 Aug 29;386(9996):856. doi: 10.1016/S0140-6736(15)00016-1. Lancet. 2015. PMID: 26335883 No abstract available.

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. Hézode C, et al. Lancet. 2015 Jun 20;385(9986):2502-9. doi: 10.1016/S0140-6736(15)60159-3. Epub 2015 Mar 31. Lancet. 2015. PMID: 25837829 Clinical Trial.